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Abstract The orphan G protein-coupled receptor APJ has been
shown to be a coreceptor for human and simian immunodefi-
ciency virus (HIV and SIV) strains. We have determined that
some HIV and SIV strains use APJ as a coreceptor to infect the
brain-derived NP-2/CD4 cells. Because apelin is an endogenous
ligand for the APJ receptor, we examined the inhibitory effects
of apelin peptides on HIV infection, and found that the apelin
peptides inhibit the entry of some HIV-1 and HIV-2 into the NP-
2/CD4 cells expressing APJ. The inhibitory efficiency has been
found to be in the order of apelin-36s apelin-17s apelin-
13s apelin-12.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
Recent studies have shown that human immunode¢ciency
virus (HIV) entry into target cells requires binding of the viral
envelope protein to CD4, followed by interaction with one of
several coreceptors. The macrophage-tropic HIV-1 uses CCR5
as a coreceptor, while T cell line-tropic (T-tropic) HIV-1 uses
CXCR4 [1^5]. Dual-tropic HIV-1 that can infect T cell lines
and macrophages uses both CCR5 and CXCR4, and occa-
sionally other chemokine receptors such as CCR2b and
CCR3 [3,4]. The endogenous ligands for CCR5, RANTES,
MIP-1K, and MIP-1L, block HIV-1 entry [6,7], whereas stro-
mal cell-derived factor-1 (SDF-1) inhibits the entry of viruses
that utilize CXCR4 as a coreceptor [8,9].
HIV-2 and simian immunode¢ciency virus (SIV) strains
also use coreceptors for their entry. Most SIV strains use
CCR5 as a coreceptor [10^12], while many HIV-2 strains
use CCR5, CXCR4, or both [13^15]. Several HIV and SIV
strains can use other chemokine receptors such as CCR8
[16,17], GPR15, STRL33/Bonzo [18,19], and US28 [20] as
coreceptors. It has recently been reported that the orphan G
protein-coupled receptor APJ [21] is a coreceptor for the T-
tropic and dual-tropic HIV-1 and SIV strains [22^24]. Several
viruses utilize APJ as a viral coreceptor almost as e⁄ciently as
CCR5 and CXCR4 in cell-to-cell infection [23]. APJ is widely
expressed in many regions of the central nervous system in-
cluding hippocampus, striatum, thalamus, cortex, cerebellum,
and spinal cord [25] as well as in NT2N neurons [23]. The APJ
transcripts are also detected in the spleen, thymus, prostate,
testis, ovary, small intestine, and colonic mucosa. Further-
more, APJ transcripts are detected in CD4-positive T cells
such as C8166 [23].
The novel peptide apelin was discovered as an endogenous
ligand for the APJ receptor [26]. The 36-amino acid peptide,
apelin-36, was isolated from bovine stomach extracts by mon-
itoring the increase in the extracellular acidi¢cation rate in-
duced by the receptor^ligand interaction in the APJ-express-
ing cells. Subsequently, apelin-36 has been shown to be
derived from the C-terminal portion of the 77-amino acid
preproprotein. In further studies, it was found that synthetic
apelin-13 and apelin-17, the C-terminal fragments of apelin-
36, exhibit much higher acidi¢cation-rate-promoting activities
than apelin-36 [26]. These results suggest that the C-terminal
portion of apelin-36 may be responsible for its receptor bind-
ing and biological activity.
In this study, we have shown that APJ acts as a coreceptor
for cell-free HIV and SIV using brain-derived glioma NP-2
cells expressing CD4 [27]. Because apelin is an endogenous
ligand for the APJ receptor, we examined the e¡ects of apelin
peptides on the entry of HIV in association with CD4, and
found, for the ¢rst time, that these peptides block cellular
entry of HIV.
2. Materials and methods
2.1. Virus strains
The HIV-1 (IIIB, GUN1, GUN1v, GUN4, and GUN7), HIV-2
(CBL-20, CBL-21, CBL-23, GH-1, and ROD/B), and SIV (agm-
TYO-1, mac251, and mndGB-1) strains were propagated in Molt-4
T cells. The HIV-1 (GUN2, GUN3, GUN12, GUN12v) and HIV-2
SBL6669 strains were produced in C8166 T cells. HIV-1 Ba-L strain
was propagated in the peripheral blood lymphocytes prepared after
Ficoll-Hypaque centrifugation of the blood from healthy donors.
2.2. Chemical synthesis of apelin peptides
Apelin-36, apelin-17, apelin-13, apelin-12, and apelin-11 were syn-
thesized by a solid-phase synthetic technique using an automatic pep-
tide synthesizer (Model 431, Applied Biosystems) and puri¢ed by
HPLC after deprotection. Structures of the synthetic peptide prepa-
rations were con¢rmed by mass spectrometric measurements using a
matrix-assisted laser desorption ionization mass spectrometer (Kom-
pact MALD III, Kratas) and by amino acid sequence analysis using a
protein sequencer (Model 477A, Applied Biosystems).
2.3. Preparation of the NP-2 cells expressing human APJ
The 1143-bp cDNA encoding APJ was cloned from a Molt-4
cDNA library by speci¢c PCR primers containing BamHI (5P) and
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NotI (3P) cloning sites. The PCR product was cloned into a pCR 2.1
TA vector (Invitrogen) and the sequence of the product was con-
¢rmed by DNA sequence analysis. The cDNA obtained from the
plasmid was subcloned into a retroviral vector pMX-puro that con-
tains a puromycin selection marker. The plasmid DNA was trans-
fected into PNX-A packaging cells to make pseudotyped virus stocks
to infect NP2/CD4 and NP2 cells [27]. APJ-transduced NP-2 and NP-
2/CD4 cells were subsequently selected in puromycin-containing me-
dium. The surviving cells were then examined for their susceptibilities
to HIV and SIV infection. The expression of APJ mRNA in the
puromycin-resistant cells was con¢rmed by a reverse transcription
polymerase chain reaction (RT-PCR) method using a speci¢c PCR
primer pair. NP-2/CD4 cells expressing human CCR5 and CXCR4
were established as described elsewhere [27].
2.4. Assay of cell-free HIV infection
Reverse transcriptase (RT) activities of the virus stocks of HIV and
SIV strains were determined as described previously [28]. NP-2, NP-2/
CD4, NP-2/APJ, and NP-2/CD4/APJ cells were seeded at a density of
3^5U104 cells/ml. On the following day, the cells were inoculated with
the virus stock corresponding to an RT activity of 1U105 cpm at
37‡C for 2 h. Cells were washed and cultured at 37‡C for up to 10
days. Culture supernatants were harvested on day 0 (2 h after infec-
tion), day 5, and day 10, and subjected to the RT assays as described
[28,29]. Viral antigens expressed in infected cells were detected using
an indirect immuno£uorescence assay (IFA) [27].
2.5. Inhibition of HIV infection by apelin peptides
NP-2/CD4/APJ cells were seeded as described above and then pre-
treated with varying concentrations of synthetic apelin peptide (ape-
lin-36, apelin-17, apelin-13, or apelin-12) for 1 h at 37‡C. The cells
were then infected with the HIV or SIV stock (corresponding to an
RT activity of 1U104 cpm) for 2 h and cultured in the medium
containing the peptide. On day 4 or day 7 after infection, the percent-
age of viral antigen-positive cells was determined by IFA. Inhibition
of the infection was calculated from numbers of viral antigen-positive
cells (%) in the infected cultures with and without peptide treatment.
3. Results
3.1. APJ as a coreceptor for the HIV and SIV strains
Since APJ has been reported to be a coreceptor for HIV-1
and SIV [22^24], we examined infection of NP-2/CD4/APJ
cells with cell-free HIV and SIV. The abilities of these viruses
to infect the APJ-expressing NP-2/CD4 cells varied markedly
when their infectivities were followed during 10 days after
infection by IFA (Fig. 1). HIV-2 strains, CBL-23 and ROD/
B, most e⁄ciently infected the cells, while GH-1 and SBL6669
infected with less e⁄ciency. HIV-1 (GUN1, GUN2, GUN4,
GUN7, GUN12) also infected the cells with less e⁄ciency.
Among the SIV strains examined, only SIV mndGB-1 infected
the cells. None of the HIV and SIV strains tested in this study
infected the NP-2, NP-2/APJ, or NP-2/CD4 cells.
We also assessed the syncytium formation activities of the
HIV and SIV strains to examine infection capabilities to the
cells. We found that HIV-2 (CBL-23 and ROD/B) strains
induced extensive syncytium formation in NP-2/CD4/APJ
cells, while the other HIV and SIV strains examined formed
either few syncytia or no syncytium. These results were well
correlated with those for IFA.
3.2. HIV and SIV infection measured by RT activity
The virus production in culture £uids was detected by an
RT assay. Virus production rapidly reached a plateau after
infection of NP-2/CD4/APJ cells with the HIV-2 (ROD/B and
CBL-23) strains, but the production levels were lower in the
HIV-2 (GH-1 and SBL6669) and SIV mndGB-1 strains than
in the HIV-2 (ROD/B and CBL-23) strains.
3.3. Blocking of HIV infection by apelin peptides
Apelin peptides are endogenous ligands for the coreceptor
APJ. We have studied whether apelin peptides are capable of
blocking HIV infection. As shown in Fig. 2, it was found that
apelin peptides e⁄ciently inhibited infection of HIV-1 (GUN4
and GUN12v) and HIV-2 ROD/B strains in NP-2/CD4/APJ
cells. The order of inhibitory e⁄ciency of the infection was
Fig. 1. Infection of the APJ-expressing NP-2/CD4 cells with HIV-1,
HIV-2, and SIV. The APJ-expressing NP-2/CD4 cells were seeded
at 3^4U104 cells per well and inoculated with each virus stock
(1U105 cpm RT activity). After incubation for 5^10 days, the cells
were smeared and ¢xed, and infection (percentages of virus antigen-
positive cells) was determined by IFA.
Fig. 2. Inhibitory e¡ects of apelin peptides on the infection of NP-2/CD4/APJ cells with HIV-1 (GUN4 and GUN12v) and HIV-2 ROD/B.
NP-2/CD4/APJ cells were preincubated with the peptide at the indicated concentrations and then infected with HIV. After incubation for 4 days
(HIV-1 GUN4 and HIV-2 ROD/B) or 7 days (HIV-1 GUN12v), numbers of virus antigen-positive cells in the infected culture were determined
by IFA.
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apelin-36s apelin-17s apelin-13s apelin-12. Apelin-11 ex-
hibited no blocking e¡ect. Apelin-36 induced 50% inhibition
of HIV infection at a concentration of 0.3 Wg/ml, while apelin-
12 did so at 63 Wg/ml (Table 1). This means that apelin-36 is
200-fold more potent than apelin-12 in inhibiting HIV infec-
tion. To determine whether the inhibitory e¡ect of apelin on
HIV infection was speci¢c to the APJ receptor, the e¡ect of
apelin peptides on HIV-2 ROD/B infection was examined for
the NP-2/CD4 cells expressing CCR5 or CXCR4. No signi¢-
cant inhibition was observed with the presence of either CCR5
or CXCR4, suggesting that the blocking of HIV entry by
apelin peptides may be mediated speci¢cally through the
APJ receptors. Furthermore, MIP-K, MIP-1L, RANTES,
and SDF-1 did not block the infection by HIV-2 ROD/B in
NP-2/CD4/APJ cells.
4. Discussion
HIV requires CD4 and a coreceptor to enter the target cells.
The G protein-coupled receptor APJ has been reported to be
a coreceptor for several HIV-1 and SIV strains. In this study,
we found that apelin peptides were able to inhibit infection by
cell-free HIV-1 (GUN4 and GUN12v), and HIV-2 ROD/B in
the brain-derived NP-2/CD4 cells expressing APJ. The inhib-
itory e¡ects of the apelin peptides on HIV entry appeared to
be related to the molecular size of the peptides. Apelin-36
showed the highest infection-blocking e⁄ciency followed by
apelin-17, apelin-13 and apelin-12, in that order. Apelin-11,
which does not bind to the APJ receptor, failed to block HIV
entry, indicating that speci¢c binding to this receptor may be
required for an apelin-related peptide to block entry. The
e⁄ciency of apelin peptides at blocking HIV entry was in
sharp contrast to that of the acidi¢cation-rate-promoting ac-
tivity in the cells in which apelin-13 or apelin-17 exhibited
much higher activity than apelin-36 (Table 1). These results
suggest that the structural requirement for apelin peptides is
di¡erent between blocking of HIV infection and exhibiting
biological activity. Lee et al. [30] have recently identi¢ed the
domains of the CCR5 molecule responsible for the interaction
with the viral envelope protein gp120 using monoclonal anti-
bodies against CCR5. Their results show that the N-terminal
domain of CCR5 is important for binding to gp120, while the
extracellular loops of CCR5 are important for inducing con-
formational changes in gp120 that lead to membrane fusion
and virus infection [30]. Our results indicate that apelin-36
more e¡ectively blocks HIV infection than apelin-12 or ape-
lin-13, suggesting that not only the C-terminal portion of
apelin-36 which is responsible for the APJ receptor binding,
but also the N-terminal portion contributes signi¢cantly to the
blocking of HIV entry.
The use of alternative coreceptors such as APJ may help to
explain HIV tropism and certain kinds of pathogenesis in
vivo. Since apelin is the endogenous ligand for the APJ re-
ceptor, it will be important to study whether high levels of
endogenous apelin are associated with a delayed progression
of HIV-related diseases. AIDS patients frequently develop
serious neurological disorders such as AIDS dementia com-
plex. Since APJ is expressed widely in many regions of the
brain [25] and is also expressed in NT2N neurons [23], the
results of the present study suggest that brain cells having
both CD4 and APJ may be potential target cells for certain
HIV infections in the central nervous system.
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